These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 4020537)

  • 41. Effect of 2,5-dimethoxy-4-methylamphetamine on heart and smooth muscle contraction.
    Huang JT; Ho BT
    J Pharm Pharmacol; 1974 Jan; 26(1):69-70. PubMed ID: 4150941
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of d-lysergic acid diethylamide, d-2-bromolysergic acid diethylamide, dl-2,5-dimethoxy-4-methylamphetamine and d-amphetamine on classical conditioning of the rabbit nictitating membrane response.
    Harvey JA; Gormezano I; Cool VA
    J Pharmacol Exp Ther; 1982 May; 221(2):289-94. PubMed ID: 6122729
    [No Abstract]   [Full Text] [Related]  

  • 43. [Determination of 4-bromo-2,5-dimethoxyamphetamine (DOB) found in illicit tablets seized in Italy].
    Furnari C; Ottaviano V; Rosati F
    Ann Ist Super Sanita; 2001; 37(2):297-300. PubMed ID: 11758288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of tolerance to the hallucinogenic effects of DOM.
    Angrist B; Rotrosen J; Gershon S
    Psychopharmacologia; 1974 Apr; 36(3):203-7. PubMed ID: 4844244
    [No Abstract]   [Full Text] [Related]  

  • 45. Triphasic dose-lethality relationships for amphetamine and certain ring-substituted amphetamines in isolated or aggregated mice.
    Davis WM; Waters IW; Hatoum HT; Buelke JL; Braude MC
    Res Commun Chem Pathol Pharmacol; 1977 Aug; 17(4):575-82. PubMed ID: 578333
    [No Abstract]   [Full Text] [Related]  

  • 46. A crystallographic and theoretical study of the conformation of DOET and its significance for the hallucinogenic amphetamines.
    Horn AS; Post ML; Kennard O; Di Sanserverino R
    J Pharm Pharmacol; 1975 Jan; 27(1):13-7. PubMed ID: 235609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stereospecific requirements for hallucinogenesis.
    Shulgin AT
    J Pharm Pharmacol; 1973 Mar; 25(3):271-2. PubMed ID: 4146335
    [No Abstract]   [Full Text] [Related]  

  • 48. First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening.
    Ovaska H; Viljoen A; Puchnarewicz M; Button J; Ramsey J; Holt DW; Dargan PI; Wood DM
    Eur J Emerg Med; 2008 Dec; 15(6):354-6. PubMed ID: 19078842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psychotomimetic phenalkylamines as serotonin agonists: an SAR analysis.
    Kier LB; Glennon RA
    Life Sci; 1978 May; 22(18):1589-93. PubMed ID: 672414
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro O-demethylation of the psychotomimetic amine, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane.
    Zweig JS; Castagnoli N
    J Med Chem; 1977 Mar; 20(3):414-21. PubMed ID: 845874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion.
    Bowen JS; Davis GB; Kearney TE; Bardin J
    JAMA; 1983 Mar; 249(11):1477-9. PubMed ID: 6827726
    [No Abstract]   [Full Text] [Related]  

  • 52. Hyper-responsiveness to 5-HT2 agonists by tumour-linked arterioles in mice: consequences for tumor growth.
    Stücker O; Vicaut E; Teisseire B
    Int J Radiat Biol; 1991; 60(1-2):237-41. PubMed ID: 1677977
    [No Abstract]   [Full Text] [Related]  

  • 53. Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines.
    Shulgin AT
    Experientia; 1964 Jul; 20(7):366-7. PubMed ID: 5855670
    [No Abstract]   [Full Text] [Related]  

  • 54. Studies on radioimmunoassay for 2,5-dimethoxy-4-methylamphetamine.
    Nagamatsu K; Kido Y; Urakabo G
    Chem Pharm Bull (Tokyo); 1977 Dec; 25(12):3390-4. PubMed ID: 564751
    [No Abstract]   [Full Text] [Related]  

  • 55. Metabolic fate of 2,5-dimethoxy-4-methylamphetamine in the guinea pig and rabbit.
    Nagamatsu K; Kido Y; Urakubo G
    Chem Pharm Bull (Tokyo); 1978 Apr; 26(4):1267-73. PubMed ID: 657412
    [No Abstract]   [Full Text] [Related]  

  • 56. 4-bromo-2,5-dimethoxyamphetamine: psychoactivity, toxic effects and analytical methods.
    Delliou D
    Forensic Sci Int; 1983; 21(3):259-67. PubMed ID: 6873782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-activity studies on hallucinogenic amphetamines using molecular connectivity.
    Kier LB; Hall LH
    J Med Chem; 1977 Dec; 20(12):1631-6. PubMed ID: 592329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sulfur analogs of psychotomimetic amines.
    Nichols DE; Shulgin AT
    J Pharm Sci; 1976 Oct; 65(10):1554-6. PubMed ID: 978423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between potency and UV spectra of hallucinogenic amphetamines.
    Bailey K; Verner D
    J Pharm Sci; 1972 Mar; 61(3):480-1. PubMed ID: 5013397
    [No Abstract]   [Full Text] [Related]  

  • 60. [The treatment of certain behavioral disorders in the mentally deficient with methylamphetamine hydrochloride].
    DELAY J; PICHOT P; SICOT L
    Enfance; 1949; 2(4):277-88. PubMed ID: 15396433
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.